Prediction of heterogeneity in breast cancer immunophenotype at ductal carcinoma in situ stage?

被引:5
|
作者
Rohilla, Manish [1 ]
Bal, Amanjit [1 ]
Singh, Gurpreet [2 ]
Joshi, Kusum [1 ]
机构
[1] Post Grad Inst Med Sci & Res, Dept Histopathol, Chandigarh, India
[2] Post Grad Inst Med Sci & Res, Dept Gen Surg, Chandigarh, India
关键词
Ductal carcinoma in situ; immunohistochemistry; molecular subtypes; PROGESTERONE RECEPTORS; MOLECULAR PHENOTYPES; MAMMARY-CARCINOMA; ER-ALPHA; EXPRESSION; HER-2/NEU; ESTROGEN; DCIS; CLASSIFICATION; SUBTYPES;
D O I
10.4103/0973-1482.199541
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Ductal carcinoma in situ (DCIS) is considered a heterogeneous lesion at the molecular level. However, there is a paucity of literature about the existence of molecular subtypes in DCIS which can predict their biological behavior at the preinvasive stage. Materials and Methods: Precise prevalence of molecular subtypes of pure DCIS and DCIS component of infiltrating duct carcinoma (IDC) was evaluated using immunohistochemistry and correlated with known prognostic factors. Results: DCIS cases were classified as luminal A (46.6% in each group), luminal B (pure DCIS 20% and DCIS component of IDC 13.3%), HER2 overexpressing, basal and nonbasal (pure DCIS 3.3% and 26.6% and DCIS component of IDC 3.3% and 33.3%, respectively), and triple negative, nonbasal (pure DCIS and DCIS component of IDC 3.3% each). The molecular phenotype of DCIS correlated well with that of the coexisting IDC. Conclusions: This study demonstrated molecular heterogeneity in DCIS; however, similar molecular phenotypes were seen in the coexisting IDC suggesting that DCIS is a precursor lesion and can predict phenotype of the invasive component. This also suggests that the invasiveness of DCIS is not dependent solely on the molecular character of the tumor epithelial cells, but factors such as tumor microenvironment may play a role.
引用
收藏
页码:1249 / 1256
页数:8
相关论文
共 50 条
  • [21] Ductal Carcinoma In Situ Stage 0 Breast Cancer When Less May Be Better
    Harris, Jan Vick
    JAMA INTERNAL MEDICINE, 2016, 176 (07) : 887 - 887
  • [22] Breast Ductal Carcinoma in Situ Precursor to Invasive Breast Cancer
    Coleman, William B.
    AMERICAN JOURNAL OF PATHOLOGY, 2019, 189 (05): : 942 - 945
  • [23] Breast cancer with features of endocrine ductal carcinoma in situ
    Yang, W
    Xu, Y
    Zhang, T
    MODERN PATHOLOGY, 2006, 19 : 45A - 45A
  • [24] Breast cancer with features of endocrine ductal carcinoma in situ
    Yang, W
    Xu, Y
    Zhang, T
    LABORATORY INVESTIGATION, 2006, 86 : 45A - 45A
  • [25] Immunophenotype of ductal carcinoma in situ in BRCA germline mutation carriers
    van der Groep, Petra
    van Diest, Paul
    van der Wall, Elsken
    CELLULAR ONCOLOGY, 2008, 30 (02) : 180 - 181
  • [26] Ductal Carcinoma In Situ of the Breast
    Siziopikou, Kalliopi P.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (04) : 462 - 466
  • [27] Ductal Carcinoma In Situ of the Breast
    Vaidya, Yash
    Vaidya, Pradeep
    Vaidya, Tanvi
    INDIAN JOURNAL OF SURGERY, 2015, 77 (02) : 141 - 146
  • [28] Ductal Carcinoma In Situ of the Breast
    Lee, Richard J.
    Vallow, Laura A.
    McLaughlin, Sarah A.
    Tzou, Katherine S.
    Hines, Stephanie L.
    Peterson, Jennifer L.
    INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2012, 2012
  • [29] IN SITU DUCTAL CARCINOMA OF BREAST
    JOHNSON, J
    JACKSON, TL
    MILLER, W
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1962, 181 (11): : 1000 - &
  • [30] Ductal carcinoma in situ of the breast
    Pfisterer, J
    ONKOLOGIE, 1999, 22 : 22 - 24